High-Risk Hepatoblastoma: Results in a Pediatric Liver Transplantation Center

Abstract

Aim: Aim of the study was assess the results of the treatment of High-Risk Hepatoblastoma (HRH) in a tertiary center where all liver surgery facilities, including pediatric transplantation (LT), are available.

Methods: 91 primary liver tumors treated between 1991 and 2009 were retrospectively reviewed. HRHs as defined by the SIOP criteria (PRETEXT IV or any stage with venous involvement, extrahepatic disease, tumor rupture and <100 ng/ml serum AFP) were identified and imaging and biopsies were reviewed. The treatment consisted of total removal of the tumor, involving extended hepatectomies and LT if necessary, together with SIOPEL-guided chemotherapy.

Results: 23/57 hepatoblastomas were HRH (11F/12M). 17 were considered unresectable by standard techniques, 3 had extrahepatic disease, and 3 fulfilled both criteria. Mean age at diagnosis was 2.3±2.4 years. 3 children (referred after chemotheraphy) died without surgery. 4 had resections (2 left and 2 right trisegmentectomies). Primary LT was required in 15 children (7 cadaveric donors and 8 living related donor transplantations (LRDT), 2 of them with retrohepatic vena cava replacement), and 1 patient had rescue LT after recurrence. Mean follow-up was 4.8±2.9 years. 2 children who had undergone liver resection developed pulmonary metastases at 1.7 and 1.6 years postoperatively and survived after surgical treatment. 2 children with LT developed EBV-related lymphoma and leukemia respectively but survived. Event-free survival (EFS) at 1, 5, and 10 years was 78.3±8.6%, 63.1±10.5%, and 63.1±10.5%, respectively. 6 children died (3 without surgery, 1 after liver resection, 1 after primary LT and 1 after rescue LT). Overall survival at 1, 5 and 10 years was 78.3±21.7%, 73.2±26.8% and 73.2±26.8%. Of those with primary LT, survival at 1, 5 and 10 years was 93.3±6.4%, 93.3±6.4% and 93.3±6.4%.

Conclusions: Outstanding results in the treatment of HRH are possible in tertiary centers when referral is early (preferably at diagnosis) and specialized liver surgery and transplantation facilities are available.

hepatoblastoma - transplantation - high risk - resection

References

• 1 Parkin DM, Stiller CA, Draper GJ. et al . The international incidence of childhood cancer.  Int J Cancer. 1988;  42 511-520
• 2 Stringer MD. Liver tumors.  Semin Pediatr Surg. 2000;  9 196-208
• 3 Otte JB, de Ville de Goyet J, Reding R. Liver transplantation for hepatoblastoma: indications and contraindications in the modern era.  Pediatr Transplant. 2005;  9 557-565
• 4 Chen LE, Shepherd RW, Nadler ML. et al . Liver transplantation and chemotherapy in children with unresectable primary hepatic malignancies: development of a management algorithm.  J Pediatr Gastroenterol Nutr. 2006;  43 487-493
• 5 Towu E, Kiely E, Pierro A. et al . Outcome and complications after resection of hepatoblastoma.  J Pediatr Surg. 2004;  39 199-202 discussion 199–202
• 6 Schnater JM, Aronson DC, Plaschkes J. et al . Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group.  Cancer. 2002;  94 1111-1120
• 7 Pimpalwar AP, Sharif K, Ramani P. et al . Strategy for hepatoblastoma management: Transplant versus nontransplant surgery.  J Pediatr Surg. 2002;  37 240-245
• 8 Reynolds M, Douglass EC, Finegold M. et al . Chemotherapy can convert unresectable hepatoblastoma.  J Pediatr Surg. 1992;  27 1080-1083 discussion 1083–1084
• 9 Otte JB, Pritchard J, Aronson DC. et al . Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience.  Pediatr Blood Cancer. 2004;  42 74-83
• 10 Roebuck DJ, Aronson D, Clapuyt P. et al . 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group.  Pediatr Radiol. 2007;  37 123-132 quiz 150–249
• 11 Czauderna P, Otte JB, Aronson DC. et al . Guidelines for surgical treatment of hepatoblastoma in the modern era – recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL).  Eur J Cancer. 2005;  41 1031-1036
• 12 Perilongo G, Shafford E, Maibach R. et al . Risk-adapted treatment for childhood hepatoblastoma final report of the second study of the International Society of Paediatric Oncology – SIOPEL 2.  Eur J Cancer. 2004;  40 411-421
• 13 Superina RA, Bambini D, Filler RM. et al . A new technique for resecting ‘unresectable’ liver tumors.  J Pediatr Surg. 2000;  35 1294-1299
• 14 Tiao GM, Bobey N, Allen S. et al . The current management of hepatoblastoma: a combination of chemotherapy, conventional resection, and liver transplantation.  J Pediatr. 2005;  146 204-211
• 15 Hemming AW, Reed AI, Langham Jr MR. et al . Combined resection of the liver and inferior vena cava for hepatic malignancy.  Ann Surg. 2004;  239 712-719 discussion 719–721
• 16 Guerin F, Gauthier F, Martelli H. et al . Outcome of central hepatectomy for hepatoblastomas.  J Pediatr Surg. 45 555-563
• 17 Ang JP, Heath JA, Donath S. et al . Treatment outcomes for hepatoblastoma: an institution's experience over two decades.  Pediatr Surg Int. 2007;  23 103-109

Correspondence